CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 11, 2012
Result type: Reports
Project Number: SR0285-000
Product Line: Reimbursement Review

Generic Name: Fidaxomicin

Brand Name: Dificid

Manufacturer: Optimer Pharmaceuticals Canada, Inc.

Therapeutic Area: Clostridium difficile infection

Indications: Clostridium difficile infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 19, 2012

Recommendation Type: Do not list at the submitted price